What do they see?

What do they see?

Today much of the country will experience a full or partial solar eclipse. And don’t be surprised if sometime after some research group will publish a paper that examines the relationship between a solar eclipse and diabetes. This being a rare event it’s not surprising much of the nation is captivated hoping to catch a glimpse. But just what will they see?

You can ask the same question to the venture groups who just threw another $58 million into Biolinq. Keep in mind Biolinq is not a neophyte and has been around a while. The company has raised . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.